Comparison · NCT02791763-f55e62d4
Daprodustat in ND Participants vs Epoetin Beta Pegol in ND Participants: Number of ND Participants Who Used Oral Iron During the Treatment Period
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Daprodustat in ND Participants vs Epoetin Beta Pegol in ND Participants: Number of ND Participants Who Used Oral Iron During the Treatment Period. Trial comparisons, record NCT02791763-f55e62d4. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02791763-f55e62d4
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.519 | 0.425 | 0.61 | wilson | |
| Risk in group 2 | 0.45 | 0.359 | 0.543 | wilson | |
| Risk difference, group 1 minus group 2 | 0.069 | -0.0631 | 0.198 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.15 | 0.875 | 1.52 | log | |
| Odds ratio, group 1 over group 2 | 1.32 | 0.773 | 2.25 | log | |
| Number needed to treat, for one more participant with the outcome on Daprodustat in ND Participants than on Epoetin Beta Pegol in ND Participants | 14.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Daprodustat in ND Participants | Eligible ND participants received oral daprodustat (1, 2, 4, 6, 8, 12, 18 or 24 milligrams \[mg\] as recommended) dose once daily for 52 weeks. | 56 | 108 | OG000 |
| Group 2 | Epoetin Beta Pegol in ND Participants | Eligible ND participants received subcutaneous (SC) epoetin beta pegol (25, 50, 75, 100, 150, 200 or 250 microgram \[µg\] as recommended) dose once every 2 or 4 weeks for 52 weeks. | 49 | 109 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of ND Participants Who Used Oral Iron During the Treatment Period
- Description
Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. The number of ND participants who used oral iron during the treatment period were summarized.
- Time frame
- Up to week 52
- Population
- ITT Population
Source ClinicalTrials.gov
Trial
- Title
- Phase III Study of GSK1278863 in Japanese Non-dialysis (ND) and Peritoneal Dialysis (PD) Subjects With Renal Anemia
- NCT number
- NCT02791763
- Phases
- PHASE3
- Conditions
- Anaemia
- Interventions
- 1 to 4 mg tablets of GSK1278863, 6 mg GSK1278863 tablet, Epoetin beta pegol
- Lead sponsor
- GlaxoSmithKline
- Results first posted
- 2019-11-13
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02791763?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02791763-f55e62d4